Evidence Hub

Paai levocetirizine reduces the cost of PER and its CO-morbidities for society and employers

C. Bachert, N. Demarteau

2004

551 participants

Abstract

PAA1 LEVOCETIRIZINE REDUCES THE COST OF PER AND ITS CO-MORBIDITIES FOR SOCIETY AND EMPLOYERS Bachert C, Demarteau N Ghent University Hospital, Belgium; UCB pharma, Braine-l’Alleud, Belgium Persistent allergic rhinitis (PER) is a frequent disease often associated with co-morbidities (asthma, sinusitis, otitis media and upper respiratory infection) and a significant economic burden. Levocetirizine is an antihistamine, the first-line treatment of allergic rhinitis. OBJECTIVES: To determine the monetary impact of a long-term levocetirizine treatment either from a societal perspective or from an employer perspective. METHODS: XPERT trial was a 6-month double-blind placebo-controlled trial comparing levocetirizine 5mg once daily to placebo. A total of 551 patients were included (69% working). Parameters measured, all related to PER or its co-morbidities, were health care resources (medications, physician visits and hospitalizations) collected in the case report form as well as workdays and usual daily activities (UDA) lost collected through a specific questionnaire. French monetary values from 2000 were applied and compared using a bootstrap-t analysis. The societal perspective included all costs for all patients while the employer perspective included the cost of workdays lost for working patients. RESULTS: The overall cost from the societal perspective was of 412.93€ per patient per month in the placebo vs. 232.23€ in the levocetirizine group. This led to a gain of 180.70€ per…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free